Stay updated on Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page
- Check5 days agoChange DetectedAdded new navigation/help sections—How to Read a Study Record, Common Questions, and How to Join a Study—and a recruitment note stating No longer looking for participants. The Intervention / Treatment heading was normalized to Intervention/Treatment and the page revision stamp updated to v3.6.0.SummaryDifference0.4%

- Check12 days agoChange DetectedRevision: v3.5.5 indicates a minor page update. It does not change the clinical trial data, eligibility criteria, or how the page is used.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange Detected- Revision indicator updated from v3.5.3 to v3.5.4, reflecting a new build of the page.SummaryDifference0.1%

- Check54 days agoChange DetectedThe site’s release/version indicator for the ClinicalTrials.gov study page has been updated from v3.5.2 to v3.5.3, reflecting a platform or content release change rather than any modification to the study details.SummaryDifference0.1%

- Check61 days agoChange DetectedAdded Revision: v3.5.2; removed Revision: v3.5.0.SummaryDifference0.1%

- Check83 days agoChange DetectedThe study status changed from Recruiting to Active, not recruiting. Several study contact details and names were removed from the page.SummaryDifference3%

Stay in the know with updates to Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page.